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INTRODUCTION
Thoracic aortic aneurysms (TAA) are often asymptomatic but 
predispose to aortic dissections, which are associated with high 
mortality rates.1 TAAs and dissections (TAAD) can be subdi-
vided into syndromic (associated with systemic manifestations) 
and nonsyndromic forms. Most commonly, familial TAADs 
segregate in an autosomal dominant manner, but rare X-linked 
families have been described.2 So far, FLNA is the only X-linked 
gene associated with a syndromic form of TAAD, namely, peri-
ventricular nodular heterotopia type 1 (PVNH1; also known as 
the Ehlers-Danlos variant of PVNH, MIM300049). However, 
FLNA explains only a small number of the X-linked TAAD 
families.3
Marfan syndrome (MFS; MIM154700) is an autosomal dom-
inant connective tissue disorder; affected individuals present 
with ocular, skeletal, and cutaneous signs in addition to aneu-
rysm and dissection. Loeys-Dietz syndrome (LDS; MIM609192, 
MIM610168, MIM613795, MIM614816, MIM615582, and 
MIM601366) is an aneurysmal connective tissue disorder that 
can be distinguished from MFS by the unique presence of cra-
niofacial, skeletal, cutaneous, and/or vascular manifestations 
and prominently includes hypertelorism, cleft palate, or bifid 
uvula and arterial tortuosity, with aneurysms distant from the 
aortic root. In addition, aneurysms in individuals with LDS 
tend to dissect at an earlier age and smaller diameter compared 
to individuals with MFS.4 Whereas MFS is caused by mutations 
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Purpose: Thoracic aortic aneurysm and dissection (TAAD) is typi-
cally inherited in an autosomal dominant manner, but rare X-linked 
families have been described. So far, the only known X-linked gene is 
FLNA, which is associated with the periventricular nodular heteroto-
pia type of Ehlers-Danlos syndrome. However, mutations in this gene 
explain only a small number of X-linked TAAD families.
Methods: We performed targeted resequencing of 368 candidate 
genes in a cohort of 11 molecularly unexplained Marfan probands. 
Subsequently, Sanger sequencing of BGN in 360 male and 155 female 
molecularly unexplained TAAD probands was performed.
Results: We found five individuals with loss-of-function mutations 
in BGN encoding the small leucine-rich proteoglycan biglycan. The 
clinical phenotype is characterized by early-onset aortic aneurysm 
and dissection. Other recurrent findings include hypertelorism, pec-
tus deformity, joint hypermobility, contractures, and mild skeletal 
dysplasia. Fluorescent staining revealed an increase in TGF-β signal-
ing, evidenced by an increase in nuclear pSMAD2 in the aortic wall. 
Our results are in line with those of prior reports demonstrating that 
Bgn-deficient male BALB/cA mice die from aortic rupture.
Conclusion: In conclusion, BGN gene defects in humans cause an 
X-linked syndromic form of severe TAAD that is associated with 
preservation of elastic fibers and increased TGF-β signaling.
Genet Med advance online publication 15 September 2016
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in FBN1 coding for an extracellular matrix (ECM) protein,5 
LDS is caused by loss-of-function (LOF) mutations in genes 
coding for components of the transforming growth factor β 
(TGF-β) signaling pathway (TGFBR1/2, SMAD2/3, TGFB2/3).6 
Recent work has demonstrated that both MFS and LDS lead to 
dysregulation of the TGF-β signaling pathway.4,7
Biglycan deficiency in male BALB/cA mice has been shown 
to lead to sudden death due to aortic rupture, suggesting that 
biglycan might be essential for the structural integrity of the 
aortic wall. Additionally, BGN mRNA and protein expression 
are reduced in individuals with Turner syndrome (45,X),8 who 
suffer more frequently from vascular anomalies including aor-
tic dissection and rupture.9 Human mutations in BGN have not 
been described in TAAD probands.
Here, we report that BGN mutations in humans cause an 
X-linked, severe, syndromic form of TAAD, including hyper-
telorism, pectus deformity, joint hypermobility, contractures, 
and mild skeletal dysplasia.
MATeRIALs AND MeTHODs
Human participants, DNA, and aortic specimens
The study was approved by the appropriate institutional 
ethics review boards, and the required informed consent 
was obtained from all participating subjects. Additionally, 
informed consent for the publication of photos was obtained 
from the subjects or legal guardians. DNA of additional 
affected and unaffected family members was requested 
whenever it was considered informative. Aortic specimens 
from probands 3-III-2 and 5-II-1 as well as from two gen-
der-matched control samples obtained from deceased indi-
viduals who did not have cardiovascular diseases were at our 
disposal. As positive controls, we used available aortic speci-
mens from two individuals with LDS (TGFB3 mutation, 
p.Asp263His). Fibroblasts were cultured using skin biopsy 
specimens from probands 4-II-1 and 5-II-1 and two gender-
matched control individuals.
Targeted resequencing
We performed targeted resequencing of 368 ECM-related and 
TGF-β-related genes using the HaloPlex Target Enrichment 
System (Agilent Technologies, Santa Clara, CA). Samples were 
paired-end sequenced using 2 × 100 bp on a HiSeq1500 in high-
output mode (Illumina, San Diego, CA). Enrichment, data 
analysis, variant annotation, and confirmation of the variants 
were performed as previously described.10,11 GRCh37 was used 
as a reference build.
sanger sequencing and microarray
Sanger sequencing of the seven coding exons of BGN 
(RefSeq transcript NM_001711.3) was performed. The 
PCR primer sequences and reaction conditions are listed in 
Supplementary Table S1 online. PCR products were bidi-
rectionally sequenced using the BigDye Terminator Cycle 
Sequencing kit (Applied Biosystems, Carlsbad, CA) and 
separated on an ABI 3130XL Genetic Analyzer (Applied 
Biosystems). Sequences were analyzed using CLC DNA work-
bench (CLC Bio, Aarhus, Denmark). Microarray analysis 
was performed using the Illumina HumanCytoSNP12-V2.1 
BeadChip (Illumina, San Diego, CA) according to standard 
protocols. Copy-number variants (CNVs) were analyzed 
using CNV-WebStore.12
Cell culture
Skin fibroblasts were cultured in Roswell Park Memorial 
Institute medium and supplemented with 15% fetal bovine 
serum, 1% L-glutamine, 1% sodium pyruvate, 1% Penicillin/
Streptomycin, and 0.1% Primocin. Experiments were per-
formed at passages 2 to 4. The fibroblasts were incubated with 
and without puromycin (200 µg/ml) to inhibit nonsense-medi-
ated decay (NMD).
cDNA sequencing and cloning
RNA was extracted from skin fibroblasts (from proband 5-II-1) 
to identify changes in BGN splicing using the RNeasy mini kit 
(Qiagen, Valencia, CA), followed by random hexamer cDNA 
conversion with the Superscript III First-Strand Synthesis kit 
for RT-PCR (Invitrogen, ThermoFisher Scientific, Waltham, 
MA). PCR was performed on the obtained cDNA using the 
following primers: 5′-CAGAGAGGCTTCTGGGACTT-3′ and 
5′-GACGAGGGCGTAGAGGTG-3′. The resulting PCR prod-
uct was then cloned into One Shot TOP10 cells (ThermoFisher 
Scientific), after which 94 colonies were picked. The different 
splice products were sequenced with Sanger sequencing.
Histology and immunohistochemistry
Paraffin-embedded aortic tissue of affected individuals and 
of control samples were sectioned (5 µm) with the HM340E 
Microm microtome (ThermoFisher Scientific). Histological 
staining, including Verhoeff-Van Gieson and Masson’s 
Trichrome, was performed using standard protocols.
Fluorescent staining of the aortic tissue with primary 
antibodies against biglycan (AF2667, 1:40; R&D Systems, 
Minneapolis, MN), decorin (AF143, 1:40: R&D Systems), 
and pSMAD2 (04-953, 1:100; Millipore, Billerica, MA) was 
performed as previously described13 but with the following 
modifications: the secondary antibodies included chicken-
anti-goat Alexa Fluor 488 conjugate (A-21467, 1:200; Life 
Technologies, ThermoFisher Scientific) and goat-anti-
rabbit TRITC conjugate (T-2769, 1:200; Life Technologies, 
ThermoFisher Scientific), and treatment with the Fc block 
reagent was omitted from the protocol. For immunohisto-
chemistry with anti-biglycan and anti-decorin, a pretreat-
ment step with chondroitin ABC lyase (1.25 U/ml, C3667; 
Sigma-Aldrich, St. Louis, MO) was performed after depa-
raffinization.14 Confocal images were acquired using the 
UltraView imaging analysis system (PerkinElmer, Waltham, 
MA) at 20× and 40× magnification. The number of pSMAD2-
positive nuclei was counted in eight fields (40× magnifica-
tion) for the media and in four fields (40× magnification) for 
the adventitia by five blinded observers.
GeNeTICs in MeDICINe  |  Volume 19  |  Number 4  |  April 2017
388
MEESTER et al  |  BGN mutations cause thoracic aortic aneurysms and dissectionsOriginal research article
Figure 1  Mutation analysis and BGN structure. (a) Pedigrees of the families with their respective mutations. Squares represent males, circles represent 
females, filled symbols represent aortic aneurysm/dissection and/or systemic involvement, half-filled symbols represent individuals with incomplete clinical 
data, and + or − sign denotes presence or absence of BGN mutation. The brackets represent an individual who was adopted into the family. (b) Location of 
BGN on the X chromosome and identified mutations. Deletions are marked with a red bar. ATP2B3 isoform 1 represents ENST00000359149. ATP2B2 isoforms 
2 and 3 represent ENST00000370186 and ENST00000349466. (c) Conservation of residues on amino acid position 80 and position 303 in other species and 
in human DCN.
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ResULTs
Identification of BGN mutations in syndromic TAAD 
probands
After targeted resequencing of 368 ECM-related and TGF-β-
related genes in a cohort of 11 molecularly unexplained Marfan 
probands, we identified two individuals with mutations in BGN 
encoding the ECM small leucine-rich proteoglycan (SLRP) 
biglycan. In the proband (1-III-1) of family 1 (Figure 1a), we 
identified a novel nonsense mutation at amino acid position 2 
(c.5G>A, p.Trp2*, ClinVar accession number SCV000266568), 
and we identified a novel missense variant at the exon–intron 
boundary of exon 7 (A in AGgt of the donor splice site) in the 
proband (2-II-1) of family 2 (c.908A>C, p.Gln303Pro, ClinVar 
accession number SCV000266569). Only a minor effect was 
predicted on splicing (Supplementary Table S2 online), but 
no skin fibroblasts of the proband of family 2 were available 
to investigate potential aberrant splicing. However, the muta-
tion substitutes a highly conserved amino acid (Figure 1c, 
Supplementary Table S2 online). 
Subsequently, we performed Sanger sequencing of BGN in 360 
male and 155 female TAAD probands negative for mutations in 
the known TAAD genes.10 Because we were unable to amplify 
exons 2 to 8 of the BGN gene in the male probands (3-III-1 en 4-II-
1) of families 3 and 4 (Figure 1a), we suspected a partial hemi-
zygous gene deletion. The latter was confirmed by microarray 
analysis (Figure 1).We further delineated these deletions by PCR 
and Sanger sequencing across the breakpoints. In family 3, we 
identified a 21-kb deletion spanning chrX:152767424-152787984 
(ClinVar accession number SCV000266570) and comprising 
exons 2 to 8 of BGN. In family 4, we identified a larger deletion com-
prising 28 kb and spanning chrX:152768438-152795976 (ClinVar 
accession number SCV000266571), but also deleting exons 2 to 8 
of BGN. In the male proband (5-II-1) of family 5 (Figure 1a), we 
identified a novel missense mutation at the exon–intron bound-
ary of exon 2, which was predicted to lead to aberrant splicing 
because the donor splice site was affected (c.238G>A, p.Gly80Ser, 
ClinVar accession number SCV000266572, Supplementary 
Table S2 online). 
We subsequently sequenced cDNA from skin fibroblasts of 
proband 5-II-1 cultured with and without puromycin, a trans-
lational inhibitor that will stabilize out-of-frame transcripts 
that are normally destined to undergo nonsense-mediated 
mRNA decay (NMD). Three alternatively spliced products 
were observed (Figure 2). Of the total amount of BGN tran-
script, only 8% shows normal splicing. The first alternative 
product (4% representation) incorporates 45 bp of the intron 
without creating a premature stop codon. The remaining two 
alternatively spliced products incorporate 111 and 368 bp of the 
intron (with 68 and 20% representation, respectively) and do 
introduce a premature stop codon leading to NMD.
In conclusion, all identified mutations are predicted to lead to 
a partial or complete loss of function of BGN through absence 
of a functional copy of the gene, through NMD, or through pre-
dicted functional changes to protein function (Supplementary 
Table S3 online).
Clinical data
The clinical phenotype of the individuals (Figure 3) with BGN 
mutations is characterized by early-onset aortic aneurysm (as 
early as age 1; 4-II-1) and dissection (earliest at the age of 15; 
3-III-1) in male probands. In all five families, either the aortic 
root or the more distal ascending aorta was involved. In one 
Figure 2 Aberrant splicing in family 5. In the proband of family 5, three aberrantly spliced mRNAs are produced. The cDNA (converted after inhibition of 
nonsense-mediated decay with puromycin) was cloned into a vector and the number of colonies with the different products was counted (total counted n = 94).
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Figure 3 Clinical features. (a) Clinical features include hypertelorism, malar flattening, down-slanting palpebral fissures (3-II-2/3/4, 3-III-1/2, and 4-II-1), 
proptosis (3-III-1/2), joint hypermobility (4-II-1), short spatulous fingers (3-III-1/2), and camptodactyly of fingers and toes (3-III-1/2). (b) Skeletal survey of patient 
3-III-1 at age 10 years and of patient 4-II-1 at age 1.5 years. Radiograph of both hands (3-III-1) reveals asymmetry in the size of the carpal bones, with the ones 
on the right being larger. Overall, there is symmetric shortening and broadening of the metacarpals and phalanges that appear osteopenic with relatively thin 
cortices. Lateral view of the spine (3-III-1) demonstrates platyspondyly with thoracolumbar transition mild anterior tonguing. Anteroposterior view of the lower 
limbs (3-III-1) shows that the distal (sub)metaphyseal region of the femur is widened and the knee epiphyses are flattened. There is also mild undermodeling 
of the tibia with an S-shape configuration of the diaphysis. The distal tibial epiphysis is dysplastic. Skeletal radiographs of proband 4-II-1 reveal bilateral hip 
dislocation (treated conservatively), broadened and triangular middle phalanges, broad terminal phalanges, and a broad thorax.
a
b
3-III-13-III-1 4-II-1
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family, we also observed brain aneurysms in one individual 
(5-I-2; Figure 1a). Although the mitral and aortic valves 
were involved in some families (e.g., 2-III-1 and 4-I-2), insuf-
ficiency was mild. The cardiovascular phenotype in muta-
tion-carrying females ranged from unaffected upon repeated 
echocardiographic evaluation (3-II-2 and 3-I-2) over aortic 
root dilatation (4-I-2 and 5-I-2) to death due to aortic dissec-
tion (1-II-1). The initial suspected clinical (differential) diag-
noses varied between MFS (families 1 and 2), LDS (families 
3, 4, 5), and Melnick-Needles syndrome and filaminopathy 
(families 3 and 4). 
We observed nonspecific connective tissue features (e.g., pec-
tus deformities, joint hypermobility/contractures, and striae) 
and more specific manifestations of LDS (e.g., bifid uvula, 
hypertelorism, and cervical spine instability) in affected indi-
viduals. The stature of the affected patients in this series ranged 
from short (e.g., 3-III-2 and 4-II-1) to normal to high normal 
(e.g., 1-III-1, 2-III-1 and 5-II-1) when compared to unaffected 
family members. Similarly, either long fingers (families 1 and 2) 
or rather short, broad fingers (families 3 and 4, 5-I-2; Figure 3) 
were noted. Other unusual features not typically seen in MFS or 
LDS include ventricular dilatation on brain imaging (families 3 
and 4), hypertrichosis (family 3), gingival hypertrophy (fam-
ily 4), and relative macrocephaly (families 3 and 4). There is also 
evidence of skeletal dysplasia with hip dislocation (families 3 
and 4), platyspondyly (family 3), phalangeal dysplasia (families 
Figure 4 Histological and fluorescent staining. (a–d) Verhoeff-Van Gieson staining of the control sample (a), proband 3-III-2 (b), proband 5-II-1 (c), and an 
individual with LDS (d). The elastin fibers in proband 3-III-2 do not show any clear breaks. In the tissue from the individual with LDS, a clear reduction in the elastic 
fiber content is present. Scale bar indicates 5 mm. (e–h) Trichrome Masson staining of the control sample (e), proband 3-III-2 (f), proband 5-II-1 (g), and an individual 
with LDS (h). A clear reduction of collagen content is present in proband 3-III-2, whereas an increase is observed in the individual with LDS. (i–l) Biglycan staining 
of the control sample (i), proband 3-III-2 (j), proband 5-II-1 (k), and an individual with LDS (l). Biglycan is not expressed in proband 3-III-2, whereas in proband 5-II-1 
some residual expression of biglycan is present. In the proband with LDS, focal increased expression of biglycan can be observed. Scale bar indicates 25 µm. (m–p) 
pSMAD2 staining of the control sample (m), proband 3-III-2 (n), proband 5-II-1 (o), and an individual with LDS (p). No pSMAD2-positive nuclei are present in the 
control sample. In proband 3-III-2, proband 5-II-1, and the proband with LDS, an increase in pSMAD2-positive nuclei can be observed.
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3 and 4), and dysplastic epiphyses of the long bones (family 3; 
Figure 3). A detailed clinical description of the five families can 
be found in the Supplementary Data online.
structural and functional changes in the aortic wall
To investigate the collagen and elastic fiber contents of the 
aortic walls, we stained aortic walls from affected (3-III-2 and 
5-II-1) and control individuals with Verhoeff-Van Gieson and 
Trichrome Masson. The staining revealed low to normal colla-
gen content; elastin fibers appeared normal (Figure 4a–h). This 
is in contrast to what is observed in LDS individuals, in whom 
an increase in collagen production and fragmentation of elastic 
fibers are typically present.13,15
Next, we fluorescently stained the aortic tissue of the affected 
probands for biglycan (Figure 4i–l). As expected, no protein 
expression was detected in proband 3-III-2 because this pro-
band had a deletion of BGN. We observed a subtle expression 
of biglycan in proband 5-II-1 that was related to the predicted 
expression of a small amount of wild-type (WT) spliced pro-
tein. Interestingly, in individuals with LDS (TGFB3 mutation, 
p.Asp263His), we specifically observed expression of biglycan 
in areas with disorganization of the arterial structure. The latter 
is different than what has been described before in patients with 
ascending aortic aneurysms of unknown genetic origin.16
To investigate whether decorin expression was altered in 
BGN-deficient patients, we performed immunohistological 
staining of the aortic walls. Decorin is another member of the 
class I SLRP, which displays an essential role in the formation 
and deposition of collagen fibrils and was previously suggested 
to be able to compensate for biglycan loss.17 We confirmed focal 
expression of decorin in the media of the aortic walls of individ-
uals with a BGN mutation (Supplementary Figure S1 online) 
that was comparable to what has been described in aortic aneu-
rysm patients.16
Because BGN has also been suggested to be a regulator of 
TGF-β signaling,18,19 and because we observed marked phe-
notypic similarities with MFS and LDS, we hypothesized that 
an increase in TGF-β signaling could also underlie the phe-
notype seen in individuals with a BGN mutation. Therefore, 
we stained pSMAD2, a specific marker of activated canonical 
TGF-β signaling (Figure 4m–p). We observed an increase of 
pSMAD2-positive nuclei compared to controls, thus confirm-
ing an increase in TGF-β signaling. In addition, a gradient of 
increased nuclear pSMAD2 staining toward the adventitia 
was observed in proband 3-III-2 (Supplementary Figure S2 
online). The increased TGF-β signaling in the media was com-
parable to the LDS-affected individual.
DIsCUssION
The BGN gene is located on chromosome Xq28 and encodes 
the biglycan protein.20 Biglycan belongs to the SLRP class I pro-
teins and, together with other proteoglycans such as decorin, is 
mainly involved in ECM assembly and maintenance.21 It con-
sists of a small protein core (~42 kDa)14 that contains 10 leu-
cine-rich repeats (LRR)22 with two tissue-specific chondroitin 
or dermatan-sulfate glycosaminoglycan (GAG) chains attached 
to two Ser-Gly sites in the N-terminus of the core protein.23,24 
Through the core protein and GAG chains, biglycan interacts 
with many other ECM proteins, including collagen type I, II, 
III, and VI and elastin.25–28 In this manner, biglycan becomes 
sequestered in the ECM of most organs; its role seems to be 
not only that of a mechanical link between matrix components 
but also that of growth factor binding and regulation of signal-
ing. In healthy individuals, biglycan is expressed by various 
specialized cell types, including endothelial cells, skeletal myo-
cytes, and differentiating keratinocytes.14 It is widely expressed 
in various tissues throughout the body, including bone, skin, 
heart, lung, and arteries.14,29 In the aorta, biglycan is present in 
the intima and the media,14 but the adventitia is the major site 
of deposition.17
Due to the suggested structural role of biglycan, we performed 
histological staining to assess the architecture of the aortic wall. 
We observed a normal appearance of elastic fibers and low to 
normal collagen content in the aortic wall of our probands. This 
is in contrast to what has been described for MFS and LDS aor-
tic tissue, where an increase in collagen content and an increase 
in elastic fiber breaks are typically observed.15,30,31 As observed 
in bgn-deficient mice, we hypothesize that proper functioning 
of biglycan is necessary for correct collagen fibril diameters and 
lateral association of fibers rather than collagen amount.32
In addition to its structural role, biglycan interacts with 
several growth factors and cytokines, including TGF-β,18,19 to 
modulate proliferation, migration, and differentiation of cells.33 
This regulatory function resembles that of fibrillin-1, which 
also forms a reservoir for latent TGF-β.7 Our results indicate 
that lack of biglycan increases TGF-β signaling, especially in 
the adventitia, the major site of biglycan deposition in the aortic 
wall.17 This may explain why BGN deficiency has a more pro-
nounced effect on TGF-β signaling in this layer of the aortic 
wall.17 Until now, the upregulation of TGF-β signaling in other 
syndromic forms of TAAD, like MFS and LDS, has mainly 
been studied in the media of the aortic wall.15 In individuals 
with a BGN mutation, we observed a slight increase in TGF-β 
signaling in the media; however, this increase was significantly 
more pronounced in the adventitia (Supplementary Figure S2 
online). The increase in TGF-β signaling is expected to lead 
to an increased transcription of collagen, but proper collagen 
fibril assembly may be hampered by biglycan deficiency. Our 
findings of increased TGF-β signaling are in line with prior 
observations of enhanced SMAD2 phosphorylation in bgn+/− 
cardiac fibroblasts.34 The latter induced differentiation into a 
pro-proliferative myofibroblast phenotype that is rescued by 
TGF-β neutralizing antibodies. 
The absence of an aortic phenotype in the pure C57Bl6 Bgn-
deficient mice35 confirms our hypothesis of increased TGF-β 
signaling as the driving pathogenetic mechanism of the aor-
tic aneurysm development. The C57Bl6 mouse background 
is believed to induce a relative deficiency state for TGF-β 
signaling and, as such, attenuates high TGF-β signaling in 
Bgn-deficient aortic walls. Only in male BALB/cA mice does 
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biglycan deficiency lead to sudden death from aortic rupture, 
indicating that biglycan is both structurally and functionally 
essential for the integrity of the aortic wall.17 The molecular 
mechanism for the difference between the pure C57Bl6 and the 
BALB/cA backgrounds remains unknown.
As a consequence of the mice studies discussed, biglycan 
gene defects were predicted to play a potential role in the 
pathogenesis of aortic dissection and rupture in humans.17 
Yet, this study is the first to report BGN mutations in TAAD 
probands. In Bgn knockout mice, aortic elastic lamella did 
not display any structural changes,17 similar to the human 
BGN probands. These normal elastic fibers can potentially be 
explained by the ability of decorin to substitute for biglycan 
in pathological contexts.17 Decorin is another member of the 
class I SLRP, which displays an essential role in the formation 
and deposition of collagen fibrils and, like biglycan, is able to 
bind tropoelastin, fibrillin-1, and microfibril-associated gly-
coprotein 1.26,36 However, its expression pattern is somewhat 
different from that of biglycan and, depending on the tissue, 
its synergistic or additive effects with biglycan can differ.37 
Bgn/Dcn double-knockout mice on a 129Sv/C57BL6 back-
ground have been generated, but an aortic phenotype has not 
been extensively studied.37 As such, it might be interesting to 
study the aortic phenotype of the Bgn/Dcn double-knockout 
mice on a BALB/cA background.
In addition to their cardiovascular phenotype, Bgn-deficient 
mice have also been reported to show a phenotype character-
ized by growth failure, reduced bone formation, and age-related 
severe osteopenia.32 Previous research has indicated that the 
expression levels of biglycan are potentially related to stature in 
humans: patients with Turner syndrome have low levels of big-
lycan and typically display short stature, whereas patients with 
triple X syndrome present with increased limb length and high 
levels of biglycan.32 In families 3 and 4, affected male individu-
als presented short stature (Table 1) and mild skeletal dyspla-
sia (Figure 3b), confirming a role for biglycan in human bone 
development.
From a clinical perspective, the phenotype of BGN-mutated 
individuals overlaps with LDS and MFS individuals. Typical 
LDS features in families 3 and 4 include pronounced hyper-
telorism, bifid uvula, and early-onset aortic dissections. The 
probands of families 1 and 2 were initially diagnosed with 
MFS, but they also displayed LDS-like features such as hyper-
telorism. The phenotype of the carrier females ranges from 
unaffected upon repeated echocardiographic examination 
(3-II-2 and 3-I-2) over aortic root dilatation (4-I-2 and 5-I-2) 
to death due to aortic dissection (1-II-1). Overall, the noncar-
diovascular characteristics of the female carriers seem milder. 
To determine whether skewed X inactivation underlies the dif-
ference between affected and unaffected females, we performed 
X-inactivation experiments using the HUMARA assay.38 The 
results did not reveal a clear pattern of skewed X inactivation 
that could explain the observed difference (data not shown). 
The phenotypic features in families 3 and 4 seemed more 
pronounced than in the other families. Complete LOF cannot 
explain this difference between the families because we also 
expect a complete LOF in family 1 due to the stop codon at 
the second amino acid position (even if the first downstream 
ATG would be used as an alternative start codon, the resulting 
protein would miss the signal and the propeptide of biglycan, 
and thus still lead to LOF). However, the deletion occurring 
in families 3 and family 4 extends beyond exons 2–8 of BGN 
and includes a region downstream of the BGN gene that con-
tains a CpG island and, in addition, the untranslated region 
(5ʹ-UTR) of two alternative protein coding transcripts of the 
downstream gene ATP2B3. So far, mutations in ATP2B3 are 
linked to an X-linked form of spinocerebellar ataxia39,40 and 
therefore cannot be directly linked to the phenotype of the 
BGN probands. Nonetheless, (intronic) regulatory elements 
may play a role in the expression of the phenotype and explain 
the observed difference. The milder phenotype in family 5 
could be correlated with 8% residual expression of WT spliced 
biglycan protein.
In conclusion, our results confirm that BGN gene defects in 
humans cause an X-linked syndromic form of severe TAAD. 
The identification of mutations in BGN contributes to the 
molecular diagnosis of X-linked TAAD and should therefore be 
implemented in diagnostics. The signature of increased TGF-β 
signaling in the aortic walls of the BGN-deficient patients offers 
an interesting therapeutic target for TGF-β activity attenuating 
agents such as angiotensin receptor blockers.
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